Kadimastem Ltd (TA:KDST) — Market Cap & Net Worth
Market Cap & Net Worth: Kadimastem Ltd (KDST)
Kadimastem Ltd (TA:KDST) has a market capitalization of $22.18 Million (ILA8.27 Billion) as of June 4, 2026. Listed on the TA stock exchange, this Israel-based company holds position #24751 globally and #359 in its home market, demonstrating a -8.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kadimastem Ltd's stock price ILA2794.00 by its total outstanding shares 2960744 (2.96 Million). Review debt load of Kadimastem Ltd to assess the company's total debt and financial obligations.
Kadimastem Ltd Market Cap History: 2015 to 2025
Kadimastem Ltd's market capitalization history from 2015 to 2025. Data shows change from $494.37 Million to $22.18 Million (-22.73% CAGR).
Kadimastem Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kadimastem Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
53.43x
Kadimastem Ltd's market cap is 53.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $494.37 Million | $1.03 Million | -$17.06 Million | 480.91x | N/A |
| 2016 | $424.19 Million | $1.70 Million | -$19.97 Million | 249.09x | N/A |
| 2017 | $36.55 Million | $684.00K | -$21.43 Million | 53.43x | N/A |
Competitor Companies of KDST by Market Capitalization
Companies near Kadimastem Ltd in the global market cap rankings as of June 4, 2026.
Key companies related to Kadimastem Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #227 globally with a market cap of $108.72 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $63.77 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #581 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #602 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #227 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.72 Billion | $428.34 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.77 Billion | $618.95 |
| #581 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #602 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Kadimastem Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Kadimastem Ltd's market cap moved from $494.37 Million to $ 22.18 Million, with a yearly change of -22.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | ILA22.18 Million | +115.75% |
| 2024 | ILA10.28 Million | +116.56% |
| 2023 | ILA4.75 Million | -50.17% |
| 2022 | ILA9.53 Million | -65.10% |
| 2021 | ILA27.30 Million | +73.65% |
| 2020 | ILA15.72 Million | -60.96% |
| 2019 | ILA40.27 Million | -31.76% |
| 2018 | ILA59.01 Million | +61.44% |
| 2017 | ILA36.55 Million | -91.38% |
| 2016 | ILA424.19 Million | -14.20% |
| 2015 | ILA494.37 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 4th, 2026 the market cap of Kadimastem Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.18 Million USD |
| MoneyControl | $22.18 Million USD |
| MarketWatch | $22.18 Million USD |
| marketcap.company | $22.18 Million USD |
| Reuters | $22.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kadimastem Ltd
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a cli… Read more